Compare Neurocrine Biosciences Inc (NBIX) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs STMicroelectronics NV — how do they compare? Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B), while STMicroelectronics NV trades at $52.14 (market cap $48.14B). The key difference: STMicroelectronics NV is far larger — about 3.4× Neurocrine Biosciences Inc's market cap, and STMicroelectronics NV pays a 0.68% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and STMicroelectronics NV for 64 Days on average.
| NBIX | STM | |
|---|---|---|
Market Cap | $14.36B | $48.14B |
Volume | 1,237,180 | 9,776,015 |
Sector | Health | Technology |
52-Week High | $185.50 | $79.91 |
52-Week Low | $123.10 | $21.20 |
Typical Hold Time | 23 Days | 64 Days |
Enterprise Value | $14.37B | $45.66B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
STM (STMicroelectronics) trades at $51.88, down 7.65% on the day, amid a bearish technical signal. The stock shows mixed fundamentals with a high P/E of 101.49 and negative net income margin of -0.39%, though Q2 2026 EPS beat expectations. Recent news highlights recovery in automotive and industrial demand, with AI data-center revenue projected to exceed $2 billion by 2027. Cash flow improved in 2025 with net cash flow of $555 million, while the balance sheet remains solid with total assets of $24.74 billion.
The outlook is cautiously optimistic given analyst consensus favoring Buy ratings (51.72%) and a $77.31 price target, implying significant upside. Key risks include earnings volatility, competitive pressures in semiconductors, and macroeconomic headwinds. Near-term performance hinges on execution of AI and automotive growth initiatives, with Q3 2026 earnings as a critical catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
